Premium
The von Hippel‐Lindau gene
Author(s) -
Clark Peter E.,
Cookson Michael S.
Publication year - 2008
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.23645
Subject(s) - medicine , renal cell carcinoma , gene , cancer , cancer research , disease , von hippel–lindau disease , kidney cancer , bioinformatics , mechanism (biology) , genetics , biology , pathology , philosophy , epistemology
Mutations or aberrations of the von Hippel‐Lindau gene are responsible for the hereditary neoplastic syndrome that bears the same name, as well as for the majority of sporadic clear cell renal cell carcinomas. The discovery of this gene and subsequent clarification of its mechanism of action have led to a series of targeted treatments for advanced kidney cancer and have dramatically changed how we manage this disease. The discovery of the VHL gene is a prime example of how discoveries at the bench can inform and revolutionize therapeutics at the bedside. In this review, the authors trace this illuminating tale, from the cloning of the VHL gene, to elucidating its biologic function, to the development of novel therapeutics that have dramatically changed the paradigm of managing advanced renal cell carcinoma. Cancer 2008;113(7 suppl):1768–78. © 2008 American Cancer Society.